Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa
Rinpei
R
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan.
Hatanaka
Shigeki
S
Shoji-Hosaka
Emi
E
Sakurada
Mikiko
M
Kobayashi
Yukari
Y
Uehara
Aya
A
Yokoi
Haruhiko
H
Nakamura
Kazuyasu
K
Shitara
Kenya
K
D000483:Alleles; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000737:chemistry; D000920:Antibody-Dependent Cell Cytotoxicity; D018951:Antigens, CD20 / Q000096:biosynthesis; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005643:Fucose / Q000737:chemistry* / Q000378:metabolism; D005838:Genotype; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry*; D007694:Killer Cells, Natural / Q000166:cytology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D009000:Monocytes / Q000378:metabolism; D009504:Neutrophils / Q000166:cytology; D010641:Phenotype; D011110:Polymorphism, Genetic; D011485:Protein Binding; D017452:Receptors, IgG / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry; D000069283:Rituximab; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D018951:Antigens, CD20; D007074:Immunoglobulin G; D017452:Receptors, IgG; D011994:Recombinant Proteins; D005643:Fucose; D000069283:Rituximab